Bilderbergers/Rummy profits via avian flu fear, as anthrax hit profited Bush Carlyle Corp.
Jack up prices by creating artificial scarcity and fearmongering about a non-existent threat--or a threat that is entirely orchestrated. And who owns stock in Tamiflu? Rumsfeld and top Bilderbergers.
This is similar to the "anthrax attacks" of 9-11 that skyrocketed sales of Bush-connected Bayer monopoly on Cipro vaccine, that the Bush Administration protected and let price gouge even after the anthrax attacks. Result: Bayer made millions out of the scare in 2001 right before its monopoly runs out in 2003. The same thing was done in Gulf War One with George H. W. Bush's connection to the anthrax vaccines and other non-tested vaccines being pushed into U.S. troops--only about five years after after GHW BUSH, REAGAN, AND RUMSFELD sold Saddam anthrax bioweaponry--that then, U.S. troops were forced to buy anthrax vaccine under GHW Bush as Bush set up Gulf War One, blah, blah...ad nauseum. You get the picture. Profit in the sales of bioweaponry and intentionally seeded risks equals profits in the sales of vaccines. The "threat-vaccine two step" linked Rumsfeld and Bushes in the mid 1980s, and links them now. Is the same being done with the avian flu? Three articles below and some background on the Bush public political protections of the anthrax vaccine monopoly--that led back to Bush connected private corporations--during the October 2001 "anthrax attacks" that actually ended up being bioweaponry materials from a Ft. Detrick strain of anthrax. What goes around comes around: they will keep doing this double profit from bioweaponry scares and vaccine production over and over, until you stop them.
Bilderbergers, Rumsfeld Profit from Avian Flu Scam
Global News Matrix | October 24 2005
You can't make any real money without a boogeyman, and the new "Bird Flu" hoax is the latest scam used to generate profits for pharmaceutical company insiders.
"Finally, the pieces of the puzzle start to add up," writes Dr. Joseph Mercola, author of the "Total Health Program." "President Bush sought to instill panic in this country by telling us a minimum of 200,000 people will die from the avian flu pandemic but it could be as bad as 2 million deaths in this country alone."
"This hoax is then used to justify the immediate purchase of 80 million doses of Tamiflu, a worthless drug that in no way shape or form treats the avian flu, but only decreases the amount of days one is sick and can actually contribute to the virus having more lethal mutations," Mercola continues.
"So the U.S. placed an order for 20 million doses of this worthless drug at a price of $100 per dose. That comes to a staggering $2 billion.
US Defense Secretary Donald Rumsfeld, former chairman of Gilead, the manufacturer of Tamiflu, will also make big profits, since he is a major shareholder.
Better yet, Bilderberger spokesman Etienne F. Davignon (Vice-Chairman, Suez-Tractebel) and Reagan-Bush Cabal insider former Secretary of State George P. Shultz, PhD (Distinguished Fellow, Hoover Institution, Stanford University) are also on the board of directors of Gilead. ( http://www.gilead.com/wt/sec/bod)
Another Bilderberger regular is Lodewijk J.R. de Vink, who sits on the board of Hoffman-La Roche, Gilead's partner.
In other words, the "Bird Flu" scam will generate outrageous profits for globalist-insiders like Shultz, Rumsfeld, Davignon, and de Vink.
And where did Tamiflu come from?
According to the Gilead website, "In September 1996, Gilead and F. Hoffmann-La Roche Ltd. entered into a collaborative agreement to develop and market therapies that treat and prevent viral influenza. Under the agreement, Roche received exclusive worldwide rights to Gilead's proprietary influenza neuraminidase inhibitors, including orally administered Tamiflu (oseltamivir phosphate), formerly known as GS 4104. As part of this collaboration, Gilead and Roche jointly conducted clinical development of oseltamivir phosphate, with Roche funding all research and development costs.Roche has worldwide commercial rights to Tamiflu, and Gilead receives payments from Roche for the successful completion of program milestones and royalties on product sales." ( http://www.gilead.com/wt/sec/partners)
It should be remembered that Rumsfeld loves pharmaceutical scams. It was after all Rumsfeld, as chairman of G.D. Searle, who pressured the FDA to get Aspartame approved.
The FDA blocked its approval for ten years before Rumsfeld twisted arms and broke who knows how many legs at the FDA. Now Aspartame, an artificial sweetener as ubiquitous as it is toxic, continues to poison America and the world.
So here's an advertising tagline.
Tamiflu -- It's the Bird-Flu Scam-Drug For You
Roche makes a killing
As panic spreads over avian flu, the Swiss pharmaceutical giant is accused of putting profits before people. Nick Mathiason reports
Sunday October 23, 2005
For the obsessively guarded, conservatively dressed and unflamboyant Oeri, Hoffman and Sacher families, avian flu could be good news. Over the next two years, the heirs of Fritz Hoffman, founders of Roche, one of the world's most powerful pharmaceutical companies, and who already rank as among the world's richest families, could see their combined £10 billion fortune reach giddy heights.
Twenty members of the founding family control Roche, which industry analysts estimate will benefit from the Tamiflu drug thought to relieve the symptoms of avian flu, with extra profits of £500 million this year and £1bn next.
And since the family owns about 10 per cent of shares and crucially 50.01 per cent of voting rights, they will ensure that no outside interests seize their company and enjoy the profits - though many would like to.
As avian flu spreads from south east Asia into Europe, sparking fears of a worldwide epidemic that medical experts say could claim 50 million lives, Roche, famous as the company behind the Valium tranquilliser, appears poised to clean up. The Basel-based company is already the fastest growing drugs firm in the world with a share performance to match. Investor returns have increased 50 per cent in a year. Last week its share price reached record highs after it said third-quarter profits rose by 20 per cent to £3.9bn.
And that growth is primarily due to a drug it did not even invent. It was US biotech firm Gilead that developed Tamiflu. But nine years ago, Gilead signed a development and licensing agreement with Roche.
It is currently the subject of legal action which will be resolved in a year. Gilead claims Roche has been negligent in its manufacture of Tamiflu which has led, Gilead says, to a series of product recalls. Gilead also says Roche has failed to market the product well, which has reduced the potential revenue the drug could have made. Roche categorically refutes the allegations.
But as legal action rumbles, Roche faces other possibly more serious threats. The firm is under unrelenting pressure to increase production of Tamiflu. In the US, senator Charles Schumer has threatened legislation compulsory to license Tamiflu unless Roche allowed generic producers to boost the number of pills in circulation. [and thus lower the price, which as seen in the third article below, is hardly something that they want to do, and have stated publicly they are going to intentionally slow down production to keep the price higher.]
The senior Democratic senator for New York accused Roche of 'putting profits ahead of world safety'. He has threatened with other Republicans to introduce legislation to force Roche to relax its stranglehold on the drug.
Pressure appears to have paid off. Last Thursday, after a month of holding its position, Roche said it would talk to four generic drug manufacturers about increasing production.
But health campaigners say this is no guarantee that Roche will act. And if it does, it will delay matters as long as possible so it gets the most revenue possible before low-cost manufacturers get in on the act.
Michael Bailey, of campaigning group Oxfam says: 'This situation is absurd. A government will have to make a move because Roche seemingly can't deliver. It's a classic case of international intellectual property law not working. It seems Roche is holding on as long as possible before allowing generic companies the right to produce so it can make as much cash as possible.'
Roche says it can produce 10 million treatments each year and so far 40 governments have placed orders for Tamiflu; It says that although any government ordering a bulk supply should expect to wait a year before its order is satisfied, generic firms have to prove that they can safely manufacture Tamiflu as there are 10 complicated steps involved in its production.
While Roche is coming under intense scrutiny, the financial community is hugely supportive of the company. After all, today it is possibly Europe's best performing drug firm thanks to its investment in biotechnology companies way before other drug majors.
Much of its profits are due to its 55 per cent stake in Genentech, the US biotechnology company behind targeted cancer drugs such as MabThera and Avastin.
The company has strengthened its diagnostic division and is leading moves to tailor drugs to individual patients through the use of new technologies.
Denise Anderson, head of healthcare at Kepler Equities, says: 'They have made paradigm changing moves. They think more carefully about trends. They just started talking about healthcare IT. Right now they are in a sweetspot where successful drugs are coming on stream and I expect that to last for a good few years.'
Roche has resolutely rejected merger offers. Novartis, its bigger rival, also from Switzerland, bought a near third share in the company four years ago. It has long been thought that this was a prelude to a merger that would produce a national Swiss champion.
But the three family clans believe mergers yield no value and divert management's energy away from day-to-day business.
Though it is Fritz Gerber and Andre Hoffman who sit on Roche's board and look after the interests of the families, Roche is run by Franz Humer, who earns £5.4m - the third biggest basic salary of any publicly quoted executive in Europe.
'The Hoffman family don't need money,' says an informed insider. 'For them it's a prestige thing. They are typically Swiss. They are conservative and do things for the long term.'
But others believe that a new generation of Roche heirs will not block a merger, as the need to create a buttress against US giant Pfizer and UK rival GlaxoSmithKline deepens.
While the pharmaceuticals industry emerged in Europe with aspirin being discovered at Bayer in Germany, its centre of gravity has shifted to the US, attracted by its research scientists and lack of price controls.
But Switzerland has a reserve of scientific expertise - Swiss drugs research papers receive more citations even than US ones.
Although its expertise is not disputed, the firm has been no stranger to controversy. In the Seventies, Stanley Adams, a Roche employee, handed over documents to the European Economic Community as it was then, detailing how the company kept the price of vitamins high with the explicit collusion of its supposed rivals. But an EEC bungle identified Adams. Roche decided to prosecute and he was imprisoned under tough Swiss commercial secrecy laws. His wife then committed suicide.
Twenty years later, Roche was at it again - marshalling a price-fixing cartel in exactly the same product. It was fined more than $500m by US and EU competition regulators.
The firm has also been singled out by health campaigners for dragging its feet in allowing Aids-devastated countries in Africa to get access to vital medicines. It was one of the 39 companies that threatened to take South Africa to court to overturn its right to produce cheap copies of expensive brand-name anti-HIV drugs.
And today though it is unclear how well Roche is helping the world prepare for what could be a devastating flu epidemic.
Firms' threat to limit bird flu vaccine
London Telegraph | October 26 2005
By Rosie Murray-West
The makers of flu vaccine yesterday threatened not to produce enough bird flu vaccine to deal with an outbreak unless ministers agreed to buy more of their products.
Richard Stubbins, of the UK Vaccine Industry Group, told a House of Lords select committee that it was "unreasonable" for the Government to expect the industry to build new plants to produce enough vaccine for a pandemic then mothball them.
He called for the Government to vaccinate everyone aged over 50 and possibly children against common flu as a matter of routine. That would guarantee that the extra capacity would be used.
The industry group represents all the companies that produce flu vaccine, including the British giant Glaxosmithkline and the French company Sanofi.
A vaccine for a feared bird flu pandemic cannot be created until the strain of the virus that can pass between humans is identified.
Mr Stubbins said the Government wanted 120 million doses of vaccine as soon as it was available but there was "a lot of work to do" before companies could produce enough to meet demand.
"We have to work very closely with the Government to find ways of increasing the productivity of the industry in as short a time as possible," he said.
One way to encourage companies to do so was to increase the use of ordinary influenza vaccines.
At the moment flu vaccination is free and recommended for people over 65 and those with chronic conditions such as asthma and diabetes. Mr Stubbins said the industry was asking health officials to increase coverage until two thirds of the population was routinely vaccinated.
The Lords' science and technology committee asked Mr Stubbins and Dr Kevin Bryett, the British head of the leading vaccine company Chiron, how long it would take for a vaccine to be ready if a pandemic emerged.
They said that it could take between 10 and 11 weeks to modify a vaccine to a particular strain of the virus and sent it to the vaccine companies. It would then be four to six months before the vaccine was ready.
Mr Stubbins said the drugs industry was trying to speed up the process by creating mock-up flu vaccines so that as much work as possible was done before a pandemic emerged and the precise strain could be activated and made into a vaccine for it.
The European Commission agreed to ban the import of most live birds for a month.
Britain had made an urgent call for the ban after the death of an imported parrot at a quarantine facility in Essex blamed on the H5N1 form of the bird flu virus - although Government vets yesterday admitted a mix-up over tests.
Margaret Beckett, the Secretary of State for Environment, Food and Rural Affairs, said she was "very pleased" at the action, while it emerged at the Brussels meeting that Britain had blocked a similar ban in March.
The ban on commercial bird imports is accompanied by restrictions on imports of pet birds.
The European Union Food Safety Agency will advise people today to avoid eating raw eggs and to make sure that poultry is cooked thoroughly.
Herman Koeter, its deputy director, said: "We do not have any evidence that the bird flu virus can be transmitted through food but we can't exclude it either." [boo, boo, buy up Tamiflu]
link to infowars.com
contribute to this article
contribute to this article
add comment to discussion